News about our Companies - MedTech Innovator

Admetsys wins Worcester’s Five Minute Pitch Contest

DateApr 15 2015

Boston-based Admetsys was the winner of The Venture Forum's ninth annual Five-Minute-Pitch contest, held in Worcester Tuesday. Admetsys CEO Jeff Valk gave the winning presentation, earning the $2,500 first prize and the $1,000 audience choice award.

Briteseed vs. Surgical Perspective

DateMar 23 2015

Briteseed has raised $46,250 in cofounder contributions; significant business plan awards, including $73,500 in cash; $1.15 million raised in seed round using a convertible note.

Admetsys Wins Top Prize at SXSW Hatch Pitch competition

DateMar 16 2015

At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.

Vixiar Medical Receives BioMaryland Development Award

DateFeb 09 2015

Vixiar Medical, Inc. announced today that it was awarded a $200,000 grant by the State of Maryland to accelerate the commercialization of its non-invasive congestive heart failure (CHF) device.

Fibralign beats 267 other startups at the 2014 MedTech Innovator competition

DateJul 14 2014

The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.

Fibralign set to bring new device option for secondary lymphedema

DateJun 26 2014

Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.